The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: ondansetron     Quarter: 2016Q3

Total Drug/Injury Combinations: 1,451     Number of Pages: 73

DRUGNAME PT EventCount
ONDANSETRON Rhinitis allergic 1 view events
ONDANSETRON Right-to-left cardiac shunt 1 view events
ONDANSETRON Scoliosis 1 view events
ONDANSETRON Selective eating disorder 1 view events
ONDANSETRON Self-medication 1 view events
ONDANSETRON Sepsis 1 view events
ONDANSETRON Shone complex 1 view events
ONDANSETRON Single functional kidney 1 view events
ONDANSETRON Small for dates baby 1 view events
ONDANSETRON Stillbirth 1 view events
ONDANSETRON Stomatitis 1 view events
ONDANSETRON Talipes 1 view events
ONDANSETRON Therapy non-responder 1 view events
ONDANSETRON Tooth development disorder 1 view events
Ondansetron Toxicity to various agents 1 view events
ONDANSETRON Tricuspid valve incompetence 1 view events
ONDANSETRON Upper respiratory tract infection 1 view events
ONDANSETRON Venoocclusive liver disease 1 view events
ONDANSETRON Ventricular fibrillation 1 view events
ONDANSETRON Ventricular hypoplasia 1 view events

Total Drug/Injury Combinations: 1,451     Number of Pages: 73

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)